ASTER DM QUALITY CARE LIMITED (ASTERDM): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹733.5 latest close · −7.5% over the last 90 sessions

₹733.5 month-end · +10.2% over 12 months

₹733.5 month-end · +91.8% over 3 years

₹733.5 month-end · +373.2% since Jan '19

52-week range ₹519.10 to ₹891.30 · 1-year volatility 29.3%

Was the rally earned?

+10%share price, 1 yearMultiple-driven

Partly.

Most of the rise came from investors paying a higher multiple (P/E 105.5x to 119.3x); per-share earnings took off 3 points.
The share count rose 6%.

Net profit growth+4 ptsNet profit rose about 4%, which lifts the price.

P/E change+13 ptsThe P/E rose from 105.5x to 119.3x, which lifts the price.

Share count change-6 ptsShare count rose 6%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with APOLLO HOSPITALS ENTERPRISES L

How rough has the ride been?

Maximum drawdown-53.0%recovered 2021-08

1-year volatility29.3%annualised

Beta vs sector index0.613-year daily, correlation 0.28

Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-53.0% (2020-02 peak to 2020-03 low, recovered 2021-08)

-38.5% (2024-04 peak to 2024-07 low, recovered 2025-01)

-31.7% (2019-01 peak to 2019-08 low, recovered 2020-01)

Most recent volume spikes

2026-08-24: 14.9x the 50-day median, price -1.4% that day

2026-08-21: 5.9x the 50-day median, price -0.5% that day

2026-08-20: 16.6x the 50-day median, price -4.3% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

119.3xP/E todayNear its historic high

Against its own history97th percentile

CheapestMedian 28.6xDearest

Usual range 5.6x to 106.7x since 2019-01.

Against Health Services119.3x vs 50.9x

This company

119.3x

Sector median

50.9x

134% above the Health Services median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE28th▼ 6 pts vs a year ago
Op. margin41st▲ 6 pts vs a year ago
Revenue growth36th▲ 7 pts vs a year ago
EPS growth21st▲ 13 pts vs a year ago
Debt/equity ↓20th▲ 8 pts vs a year ago
Cash cycle ↓91st▲ 6 pts vs a year ago
P/E ↓12th▼ 5 pts vs a year ago
12M momentum69th▼ 3 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~20%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 30.4x, a holder earning 12%/yr needs earnings to grow about 19.9%/yr for 10 years, then trade at 15x.

Delivered34.3%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg

Gap−14.4 ptsimplied minus delivered

Rank748thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	21.5%	22.6%	23.7%
15x	18.8%	19.9%	21.0%
20x	15.5%	16.5%	17.6%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 19.9%/yr

Looking back

Jan 2020Price implied 25%/yr; EPS has since grown 2%/yr (7.0 yrs)
Jan 2021Price implied 24%/yr; EPS has since grown 5%/yr (6.0 yrs)
Jan 2022Price implied 25%/yr; EPS has since grown 18%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹733.50
P/E: 119.3x
ROCE: 12.0%
Market Cap: ₹63951 cr
Revenue (TTM): ₹4876 cr
P/S: 13.1x
P/B: 15.2x
ROE: 12.8%
Operating Margin: 20.0%
Debt / Equity: 0.6x
Promoter Holding: 40.4%
12M Momentum: 10.2%

52-week range

₹519.10₹891.30

58% of the way from its 52-week low to its high

Price risk

1Y volatility

29.3%

Beta vs sector

1-year daily

0.87

Balance sheet & cash

Interest cover

operating profit ÷ interest

5.2x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.20x

low

Share count, 1Y

+3.6%

Are profits backed by cash?

6 of 7checks within range1 beyond a threshold

Other income reliance-2%Within range

Other income as a share of pre-tax profit (trailing twelve months): -2.4%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate32%Within range

Median quarterly effective tax rate over about 2.5 years: 32.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.20xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.20x (cash from operations ₹1,239 cr, net profit ₹6,047 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+1 daysWithin range

Debtor days are above the median of the previous three fiscal years by 1 days (24 vs 23). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress10% of fixed assetsWithin range

Capital work-in-progress is 10% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-15 days / 2 yrsWithin range

Days payable changed by -15 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, FIIs trimmed 30.5 pts; DIIs added 20.5 pts; promoters trimmed 1.5 pts.
The number of shareholders rose from 67,331 to 1.3 lakh (+98%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change

Promoters41.9%40.4%-1.5 pts

FIIs41.0%10.5%-30.5 pts

DIIs7.2%27.6%+20.5 pts

Public and others9.6%21.4%+11.8 pts

Number of shareholders

1.3 lakhshareholders+98% since Dec '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−10.9%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like ASTER DM QUALITY CARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −23% to +7% vs the market, against −3% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −7.8%, 80% range −15.7% to −4.0%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median

−10.9%

All companies' median

−3.1%

Beat the market

34% vs 47%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
BATAINDIA Consumer Non-Durables	Jul 2022	237x	8%	+21%	−12%	−23%
TITAN Consumer Durables	May 2022	202x	13%	+39%	−18%	+17%
GODREJPROP Finance	Jan 2024	116x	6%	+101%	−2%	−9%
MEDANTA Health Services	Feb 2024	112x	17%	+162%	−8%	−12%
VBL Consumer Non-Durables	Sep 2022	98x	17%	+75%	−11%	+56%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
INDHOTEL Consumer Services	Feb 2020	60x	8%	−3%	−16%	−33%
NAVINFLUOR Process Industries	May 2025	80x	11%	+34%	−9%	+64%
PHOENIXLTD Finance	Jan 2023	103x	5%	+37%	−12%	+27%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ASTER DM QUALITY CARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

PHOENIX MILLSPHOENIXLTD

Finance

73%similar

ROCEmarket cap

BIOCONBIOCON

Health Technology

72%similar

operating marginmarket cap

ASAHI INDIA GLASSASAHIINDIA

Consumer Durables

68%similar

revenuedebt/equity

JUBILANT FOODWORKSJUBLFOOD

Consumer Services

66%similar

operating marginpromoter holding

LENSKART SOLUTIONSLENSKART

Retail Trade

66%similar

P/Emarket cap

KRISHNA INSTITUTE OF MED SCIKIMS

Health Services

78%similar

P/Eoperating margin

DR AGARWALS HEALTH CAREAGARWALEYE

Health Services

68%similar

P/Edebt/equity

MAX HEALTHCARE INSTITUTEMAXHEALTH

Health Services

64%similar

market capvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '24

2026
OctPriceFell 26% from the Aug 2026 peak to the Oct 2026 low.
SepInstitutionsFII + DII holding fell 6.6 pts over 1 quarter to 38.2%.
SepValuationP/E crossed above the 90th percentile of its own history to date (113.4x).
AugPriceVolume reached 124.4x its 50-day median on 2026-08-19; price -2.2% that day.
MayPriceRegained the 2025-10 peak, 3 months after the low.
MayPriceVolume reached 17.7x its 50-day median on 2026-05-04; price +6.2% that day.
MarPriceVolume reached 5.9x its 50-day median on 2026-03-09; price -2.1% that day.
FebPriceFell 26% from the Oct 2025 peak to the Feb 2026 low.

Show 22 earlier events

2025
OctPriceVolume reached 7.6x its 50-day median on 2025-10-08; price +5.6% that day.
SepResultsYear-on-year EPS growth turned negative.
SepValuationP/E crossed above the 90th percentile of its own history to date (99.4x).
SepPeer rankSlipped to the bottom quartile of Health Services on EPS growth (from the top quartile).
JulPriceVolume reached 31.0x its 50-day median on 2025-07-03; price +9.6% that day.
JunPeer rankMoved into the 3rd quartile of Health Services on ROCE (from the bottom quartile).
JunDividendDividend payout cut from 4637% to 5% of profit.
JunPriceVolume reached 5.1x its 50-day median on 2025-06-16; price +2.9% that day.
MarPriceVolume reached 46.4x its 50-day median on 2025-03-28; price +6.7% that day.
FebDebtDebt / equity halved over 12 months to 0.42x.
JanPriceRegained the 2024-04 peak, 6 months after the low.
2024
DecPeer rankMoved into the 3rd quartile of Health Services on operating margin (from the bottom quartile).
OctPriceVolume reached 30.3x its 50-day median on 2024-10-24; price +10.3% that day.
SepResultsYear-on-year EPS growth turned positive.
SepInstitutionsFII + DII holding fell 4.7 pts over 2 quarters to 43.4%.
SepPeer rankSlipped to the bottom quartile of Health Services on operating margin (from the 3rd quartile).
AugPriceVolume reached 8.9x its 50-day median on 2024-08-01; price +6.1% that day.
JulPriceFell 38% from the Apr 2024 peak to the Jul 2024 low.
JulDebtDebt / equity halved over 12 months to 0.42x.
JunValuationP/E crossed above the 90th percentile of its own history to date (133.8x).
JunPeer rankSlipped to the bottom quartile of Health Services on EPS growth (from the 3rd quartile).
JunDebtDebt / equity fell below 1.0x (0.42x).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	119.3x	₹4876 cr	12.8%	12.0%	0.6x
2026-10	110.8x	₹4876 cr	12.8%	12.0%	0.6x
2026-09	113.4x	₹4876 cr	12.8%	12.0%	0.6x
2026-08	100.9x	₹4643 cr	15.0%	12.0%	0.6x
2026-07	109.8x	₹4643 cr	15.0%	12.0%	0.6x
2026-06	104.7x	₹4643 cr	15.0%	12.0%	0.6x
2026-05	114.5x	₹4461 cr	17.4%	11.0%	0.8x
2026-04	110.2x	₹4461 cr	17.4%	11.0%	0.8x
2026-03	105.3x	₹4461 cr	17.4%	11.0%	0.8x
2026-02	100.9x	₹4325 cr	17.7%	11.0%	0.8x
2026-01	85.1x	₹4325 cr	17.7%	11.0%	0.8x
2025-12	95.0x	₹4325 cr	17.7%	11.0%	0.8x
2025-11	105.5x	₹4214 cr	16.9%	11.0%	0.8x
2025-10	107.5x	₹4214 cr	16.9%	11.0%	0.8x
2025-09	99.4x	₹4214 cr	16.9%	11.0%	0.8x
2025-08	5.6x	₹4138 cr	261.6%	11.0%	0.8x
2025-07	5.6x	₹4138 cr	261.6%	11.0%	0.8x
2025-06	5.5x	₹4138 cr	261.6%	11.0%	0.8x
2025-05	5.3x	₹4112 cr	187.7%	4.0%	0.4x
2025-04	4.8x	₹4112 cr	187.7%	4.0%	0.4x
2025-03	4.6x	₹4112 cr	187.7%	4.0%	0.4x
2025-02	3.7x	₹4017 cr	192.8%	4.0%	0.4x
2025-01	4.5x	₹4017 cr	192.8%	4.0%	0.4x
2024-12	4.8x	₹4017 cr	192.8%	4.0%	0.4x
2024-11	4.7x	₹3860 cr	188.6%	4.0%	0.4x
2024-10	4.2x	₹3860 cr	188.6%	4.0%	0.4x
2024-09	3.9x	₹3860 cr	188.6%	4.0%	0.4x
2024-08	157.0x	₹3699 cr	7.5%	4.0%	0.4x
2024-07	134.0x	₹3699 cr	7.5%	4.0%	0.4x
2024-06	133.8x	₹3699 cr	7.5%	4.0%	0.4x
2024-05	42.8x	₹2994 cr	17.2%	3.0%	1.5x
2024-04	40.9x	₹2994 cr	17.2%	3.0%	1.5x
2024-03	48.1x	₹2994 cr	17.2%	3.0%	1.5x
2024-02	55.4x	₹2994 cr	17.2%	3.0%	1.5x
2024-01	52.0x	₹2994 cr	17.2%	3.0%	1.5x
2023-12	48.2x	₹2994 cr	17.2%	3.0%	1.5x
2023-11	44.9x	₹2994 cr	17.2%	3.0%	1.5x
2023-10	38.7x	₹2994 cr	17.2%	3.0%	1.5x
2023-09	38.5x	₹2994 cr	17.2%	3.0%	1.5x
2023-08	39.0x	₹2994 cr	17.2%	3.0%	1.5x
2023-07	36.7x	₹2994 cr	17.2%	3.0%	1.5x
2023-06	32.9x	₹2994 cr	17.2%	3.0%	1.5x
2023-05	25.6x	₹10253 cr	24.8%	10.0%	1.5x
2023-04	23.5x	₹10253 cr	24.8%	10.0%	1.5x
2023-03	22.9x	₹10253 cr	24.8%	10.0%	1.5x
2023-02	21.2x	₹10253 cr	24.8%	10.0%	1.5x
2023-01	20.2x	₹10253 cr	24.8%	10.0%	1.5x
2022-12	21.9x	₹10253 cr	24.8%	10.0%	1.5x
2022-11	22.5x	₹10253 cr	24.8%	10.0%	1.5x
2022-10	23.5x	₹10253 cr	24.8%	10.0%	1.5x
2022-09	24.0x	₹10253 cr	24.8%	10.0%	1.5x
2022-08	21.0x	₹10253 cr	24.8%	10.0%	1.5x
2022-07	21.8x	₹10253 cr	24.8%	10.0%	1.5x
2022-06	16.9x	₹10253 cr	24.8%	10.0%	1.5x
2022-05	67.4x	₹8608 cr	7.8%	6.0%	1.4x
2022-04	65.0x	₹8608 cr	7.8%	6.0%	1.4x
2022-03	66.7x	₹8608 cr	7.8%	6.0%	1.4x
2022-02	57.7x	₹8608 cr	7.8%	6.0%	1.4x
2022-01	62.4x	₹8608 cr	7.8%	6.0%	1.4x
2021-12	58.7x	₹8608 cr	7.8%	6.0%	1.4x
2021-11	64.9x	₹8608 cr	7.8%	6.0%	1.4x
2021-10	63.4x	₹8608 cr	7.8%	6.0%	1.4x
2021-09	70.1x	₹8608 cr	7.8%	6.0%	1.4x
2021-08	72.4x	₹8608 cr	7.8%	6.0%	1.4x
2021-07	55.2x	₹8608 cr	7.8%	6.0%	1.4x
2021-06	52.0x	₹8608 cr	7.8%	6.0%	1.4x
2021-05	26.5x	₹8652 cr	14.2%	12.0%	1.7x
2021-04	25.8x	₹8652 cr	14.2%	12.0%	1.7x
2021-03	24.8x	₹8652 cr	14.2%	12.0%	1.7x
2021-02	25.9x	₹8652 cr	14.2%	12.0%	1.7x
2021-01	28.6x	₹8652 cr	14.2%	12.0%	1.7x
2020-12	29.9x	₹8652 cr	14.2%	12.0%	1.7x
2020-11	30.2x	₹8652 cr	14.2%	12.0%	1.7x
2020-10	24.2x	₹8652 cr	14.2%	12.0%	1.7x
2020-09	23.9x	₹8652 cr	14.2%	12.0%	1.7x
2020-08	23.5x	₹8652 cr	14.2%	12.0%	1.7x
2020-07	23.9x	₹8652 cr	14.2%	12.0%	1.7x
2020-06	22.4x	₹8652 cr	14.2%	12.0%	1.7x
2020-05	13.6x	₹7963 cr	16.9%	13.0%	0.9x
2020-04	15.0x	₹7963 cr	16.9%	13.0%	0.9x
2020-03	14.4x	₹7963 cr	16.9%	13.0%	0.9x
2020-02	24.6x	₹7963 cr	16.9%	13.0%	0.9x
2020-01	25.0x	₹7963 cr	16.9%	13.0%	0.9x
2019-12	24.4x	₹7963 cr	16.9%	13.0%	0.9x
2019-11	24.3x	₹7963 cr	16.9%	13.0%	0.9x
2019-10	20.5x	₹7963 cr	16.9%	13.0%	0.9x
2019-09	17.9x	₹7963 cr	16.9%	13.0%	0.9x
2019-08	17.9x	₹7963 cr	16.9%	13.0%	0.9x
2019-07	18.7x	₹7963 cr	16.9%	13.0%	0.9x
2019-06	19.1x	₹7963 cr	16.9%	13.0%	0.9x
2019-05	28.1x	₹6721 cr	14.7%	7.0%	0.8x
2019-04	27.6x	₹6721 cr	14.7%	7.0%	0.8x
2019-03	29.0x	₹6721 cr	14.7%	7.0%	0.8x
2019-02	29.4x	₹6721 cr	14.7%	7.0%	0.8x
2019-01	29.1x	₹6721 cr	14.7%	7.0%	0.8x

Methodology and data notes